NASDAQ:ANAB AnaptysBio (ANAB) Stock Price, News & Analysis → Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (From Paradigm Press) (Ad) Free ANAB Stock Alerts $21.00 +2.13 (+11.29%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$18.72▼$21.6150-Day Range$18.87▼$26.4752-Week Range$13.36▼$27.50Volume649,169 shsAverage Volume317,988 shsMarket Capitalization$561.96 millionP/E RatioN/ADividend YieldN/APrice Target$46.22 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get AnaptysBio alerts: Email Address AnaptysBio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside120.1% Upside$46.22 Price TargetShort InterestBearish18.01% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.63Based on 3 Articles This WeekInsider TradingSelling Shares$3.59 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($6.17) to ($5.94) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.10 out of 5 starsMedical Sector345th out of 908 stocksPharmaceutical Preparations Industry153rd out of 422 stocks 4.4 Analyst's Opinion Consensus RatingAnaptysBio has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 8 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAnaptysBio has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted18.01% of the float of AnaptysBio has been sold short.Short Interest Ratio / Days to CoverAnaptysBio has a short interest ratio ("days to cover") of 13.2, which indicates bearish sentiment.Change versus previous monthShort interest in AnaptysBio has recently decreased by 0.70%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnaptysBio does not currently pay a dividend.Dividend GrowthAnaptysBio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ANAB. Previous Next 3.1 News and Social Media Coverage News SentimentAnaptysBio has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.32 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AnaptysBio this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added AnaptysBio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AnaptysBio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,586,199.00 in company stock.Percentage Held by Insiders35.50% of the stock of AnaptysBio is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AnaptysBio are expected to grow in the coming year, from ($6.17) to ($5.94) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AnaptysBio is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AnaptysBio is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnaptysBio has a P/B Ratio of 6.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)Watch my video for all of the details About AnaptysBio Stock (NASDAQ:ANAB)AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Read More ANAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ANAB Stock News HeadlinesMarch 27, 2024 | insidertrades.comDaniel Faga Sells 3,000 Shares of AnaptysBio, Inc. (NASDAQ:ANAB) StockApril 24, 2024 | prnewswire.comActym Therapeutics Appoints Thomas Smart as CEOApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 19, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on AnaptysBio, Inc.'s Q1 2024 Earnings (NASDAQ:ANAB)April 18, 2024 | americanbankingnews.comLeerink Partnrs Reiterates Outperform Rating for AnaptysBio (NASDAQ:ANAB)April 17, 2024 | msn.comLeerink Partners Initiates Coverage of AnaptysBio (ANAB) with Outperform RecommendationApril 17, 2024 | americanbankingnews.comAnaptysBio (NASDAQ:ANAB) Receives New Coverage from Analysts at SVB LeerinkApril 15, 2024 | investorplace.comBTIG Research Predicts Over 118% Rally for These 3 StocksApril 27, 2024 | Banyan Hill Publishing (Ad)Forget AI, Imperium Is Expected to Grow 320,00% in 3 YearsIf you think AI is big, then you have got to check out something I call Imperium… By my calculations, it’s set to grow 320,000% in three years. (You can see my calculations here.)April 12, 2024 | fool.comWhy AnaptysBio Stock Zoomed Nearly 8% Higher This WeekApril 1, 2024 | markets.businessinsider.comUnveiling 4 Analyst Insights On AnaptysBioMarch 18, 2024 | finance.yahoo.comIndustry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue ForecastsMarch 12, 2024 | markets.businessinsider.comSkin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical TriggersMarch 12, 2024 | seekingalpha.comWedbush raises AnaptysBio to outperform, cites upcoming dataMarch 12, 2024 | markets.businessinsider.comJ.P. Morgan Reaffirms Their Hold Rating on AnaptysBio (ANAB)March 12, 2024 | finanznachrichten.deAnaptysBio, Inc.: Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | globenewswire.comAnaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateMarch 11, 2024 | finance.yahoo.comANAB Mar 2024 20.000 callFebruary 29, 2024 | globenewswire.comAnaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual MeetingFebruary 27, 2024 | msn.comBTIG Initiates Coverage of AnaptysBio (ANAB) with Buy RecommendationFebruary 24, 2024 | msn.comAnaptysBio (ANAB) Price Target Increased by 40.21% to 38.61February 22, 2024 | benzinga.comAnaptysBio Stock (NASDAQ:ANAB) Insider TradesFebruary 22, 2024 | msn.comStifel Initiates Coverage of AnaptysBio (ANAB) with Buy RecommendationFebruary 21, 2024 | msn.comStifel starts AnaptysBio at buy, cites upcoming catalystsFebruary 21, 2024 | msn.comPalo Alto Networks, Home Depot downgraded: Wall Street's top analyst callsFebruary 21, 2024 | investing.comAnaptysbio a key player in next wave of immune cell modulatory therapies - StifelFebruary 19, 2024 | finance.yahoo.comStrength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength?See More Headlines Receive ANAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/11/2024Today4/26/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ANAB CUSIPN/A CIK1370053 Webwww.anaptysbio.com Phone(858) 362-6295FaxN/AEmployees117Year Founded2005Price Target and Rating Average Stock Price Target$46.22 High Stock Price Target$80.00 Low Stock Price Target$21.00 Potential Upside/Downside+120.1%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($6.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,620,000.00 Net Margins-953.66% Pretax Margin-953.68% Return on Equity-119.42% Return on Assets-32.58% Debt Debt-to-Equity RatioN/A Current Ratio10.87 Quick Ratio10.87 Sales & Book Value Annual Sales$17.16 million Price / Sales32.75 Cash FlowN/A Price / Cash FlowN/A Book Value$3.32 per share Price / Book6.33Miscellaneous Outstanding Shares26,760,000Free Float17,262,000Market Cap$561.96 million OptionableOptionable Beta-0.30 Social Links The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. Daniel R. Faga (Age 44)President, CEO & Director Comp: $867.12kMr. Eric J. Loumeau (Age 61)Chief Legal Officer Comp: $685.59kDr. James Newman Topper M.D. (Age 62)Ph.D., Advisor Comp: $86.5kDr. Paul F. Lizzul FAAD (Age 49)M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer Comp: $656.36kMr. Dennis M. Mulroy (Age 69)Chief Financial Officer Comp: $448.81kMs. Beth MuellerSenior Vice President of Human ResourcesDr. Martin Dahl Ph.D.Senior Vice President of ResearchMr. Benjamin StoneChief Business OfficerMr. Douglas A. Rich M.B.A. (Age 55)Senior Vice President of CMC Ms. Monique Da SilvaSenior Vice President of Corporate AffairsMore ExecutivesKey CompetitorsCOMPASS PathwaysNASDAQ:CMPSStoke TherapeuticsNASDAQ:STOKArriVent BioPharmaNASDAQ:AVBPAstria TherapeuticsNASDAQ:ATXSPhathom PharmaceuticalsNASDAQ:PHATView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCBought 1,688 shares on 4/18/2024Ownership: 0.006%Daniel FagaSold 3,000 sharesTotal: $64,260.00 ($21.42/share)Daniel FagaSold 145,940 sharesTotal: $3.32 M ($22.78/share)Fisher Asset Management LLCBought 500 shares on 3/5/2024Ownership: 0.268%Eric J LoumeauSold 5,000 sharesTotal: $125,000.00 ($25.00/share)View All Insider TransactionsView All Institutional Transactions ANAB Stock Analysis - Frequently Asked Questions Should I buy or sell AnaptysBio stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last twelve months. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ANAB shares. View ANAB analyst ratings or view top-rated stocks. What is AnaptysBio's stock price target for 2024? 10 Wall Street analysts have issued twelve-month target prices for AnaptysBio's shares. Their ANAB share price targets range from $21.00 to $80.00. On average, they expect the company's share price to reach $46.22 in the next year. This suggests a possible upside of 120.1% from the stock's current price. View analysts price targets for ANAB or view top-rated stocks among Wall Street analysts. How have ANAB shares performed in 2024? AnaptysBio's stock was trading at $21.42 on January 1st, 2024. Since then, ANAB shares have decreased by 2.0% and is now trading at $21.00. View the best growth stocks for 2024 here. When is AnaptysBio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ANAB earnings forecast. How were AnaptysBio's earnings last quarter? AnaptysBio, Inc. (NASDAQ:ANAB) announced its quarterly earnings data on Monday, March, 11th. The biotechnology company reported ($1.59) EPS for the quarter, topping analysts' consensus estimates of ($1.74) by $0.15. The biotechnology company had revenue of $9.01 million for the quarter, compared to the consensus estimate of $3.28 million. AnaptysBio had a negative net margin of 953.66% and a negative trailing twelve-month return on equity of 119.42%. What ETF holds AnaptysBio's stock? Virtus LifeSci Biotech Clinical Trials ETF holds 4,551 shares of ANAB stock, representing 0.91% of its portfolio. What other stocks do shareholders of AnaptysBio own? Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV). When did AnaptysBio IPO? AnaptysBio (ANAB) raised $60 million in an IPO on Thursday, January 26th 2017. The company issued 4,000,000 shares at $14.00-$16.00 per share. Credit Suisse and Stifel acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are AnaptysBio's major shareholders? AnaptysBio's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.01%). Insiders that own company stock include Daniel Faga, Dennis Mulroy, Ecor1 Capital, Llc, Eric J Loumeau, Eric J Loumeau, Hamza Suria and Paul F Lizzul. View institutional ownership trends. How do I buy shares of AnaptysBio? Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ANAB) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.